| pubmed-article:19641174 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19641174 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:19641174 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:19641174 | lifeskim:mentions | umls-concept:C0243020 | lld:lifeskim |
| pubmed-article:19641174 | lifeskim:mentions | umls-concept:C1333337 | lld:lifeskim |
| pubmed-article:19641174 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:19641174 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:19641174 | pubmed:issue | 17 | lld:pubmed |
| pubmed-article:19641174 | pubmed:dateCreated | 2009-9-2 | lld:pubmed |
| pubmed-article:19641174 | pubmed:abstractText | EphA2 is overexpressed in many types of human cancer but is absent or expressed at low levels in normal epithelial tissues. We investigated whether a novel immunoconjugate containing an anti-EphA2 monoclonal antibody (1C1) linked to a chemotherapeutic agent (monomethyl auristatin phenylalanine [MMAF]) through a noncleavable linker maleimidocaproyl (mc) had antitumor activity against ovarian cancer cell lines and tumor models. | lld:pubmed |
| pubmed-article:19641174 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19641174 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19641174 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19641174 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:19641174 | pubmed:issn | 1460-2105 | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:ColemanRobert... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:TiceDavid ADA | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:SoodAnil KAK | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:LeeJeong-WonJ... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:KimSeung... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:KimHye-SunHS | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:MaoShenlanS | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:JacksonDowdyD | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:LuChunhuaC | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:SchmandtRosem... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:LangleyRobert... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:LandenCharles... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:MangalaLingeg... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:NickAlpa MAM | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:HanHee DongHD | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:GooyaJohnJ | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:ShahzadMian... | lld:pubmed |
| pubmed-article:19641174 | pubmed:author | pubmed-author:FazenbakerChr... | lld:pubmed |
| pubmed-article:19641174 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19641174 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:19641174 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:19641174 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19641174 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19641174 | pubmed:pagination | 1193-205 | lld:pubmed |
| pubmed-article:19641174 | pubmed:dateRevised | 2011-8-1 | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:meshHeading | pubmed-meshheading:19641174... | lld:pubmed |
| pubmed-article:19641174 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19641174 | pubmed:articleTitle | EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. | lld:pubmed |
| pubmed-article:19641174 | pubmed:affiliation | Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. | lld:pubmed |
| pubmed-article:19641174 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19641174 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19641174 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19641174 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19641174 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19641174 | lld:pubmed |
